Literature DB >> 17917959

Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications.

Michael Pfeilstöcker1, Heidrun Karlic, Thomas Nösslinger, Wolfgang Sperr, Reinhard Stauder, Otto Krieger, Peter Valent.   

Abstract

Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid neoplasms that develop primarily in elderly patients. Although a specific molecular basis for the predominant incidence of MDS in higher age groups remains unknown, several lines of evidence suggest that the biology of aging and the pathogenesis of MDS share several genetic, epigenetic, and molecular features. The current review attempts to delineate these common aspects as well as additional discriminative features that are specific for MDS and thus help explaining disease-evolution and progression. In addition, the present review discusses age as an important prognostic factor and co-variable to be considered in treatment algorithms in MDS.

Entities:  

Mesh:

Year:  2007        PMID: 17917959     DOI: 10.1080/10428190701534382

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.

Authors:  Naval Daver; Kiran Naqvi; Elias Jabbour; Tapan Kadia; Courtney DiNardo; Marylou Cardenas-Turanzas; Sherry Pierce; Khanh Thi-Thuy Nguyen; Carlos Bueso-Ramos; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2014-02-21       Impact factor: 10.047

2.  Telomere length and anaemia in old age: results from the Newcastle 85-plus Study and the Leiden 85-plus Study.

Authors:  Wendy P J Den Elzen; Carmen Martin-Ruiz; Thomas von Zglinicki; Rudi G J Westendorp; Thomas B L Kirkwood; Jacobijn Gussekloo
Journal:  Age Ageing       Date:  2011-05-27       Impact factor: 10.668

Review 3.  Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Authors:  Roberto Castelli; Riccardo Schiavon; Valentina Rossi; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-04-19       Impact factor: 3.064

4.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.

Authors:  Kiran Naqvi; Guillermo Garcia-Manero; Sagar Sardesai; Jeong Oh; Carlos E Vigil; Sherry Pierce; Xiudong Lei; Jianqin Shan; Hagop M Kantarjian; Maria E Suarez-Almazor
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

5.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.

Authors:  Chantana Polprasert; Isabell Schulze; Mikkael A Sekeres; Hideki Makishima; Bartlomiej Przychodzen; Naoko Hosono; Jarnail Singh; Richard A Padgett; Xiaorong Gu; James G Phillips; Michael Clemente; Yvonne Parker; Daniel Lindner; Brittney Dienes; Eckhard Jankowsky; Yogen Saunthararajah; Yang Du; Kevin Oakley; Nhu Nguyen; Sudipto Mukherjee; Caroline Pabst; Lucy A Godley; Jane E Churpek; Daniel A Pollyea; Utz Krug; Wolfgang E Berdel; Hans-Ulrich Klein; Martin Dugas; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Kenichi Yoshida; Seishi Ogawa; Carsten Müller-Tidow; Jaroslaw P Maciejewski
Journal:  Cancer Cell       Date:  2015-04-23       Impact factor: 31.743

6.  Immune dysregulation in myelodysplastic syndrome.

Authors:  Chiharu Sugimori; Alan F List; Pearlie K Epling-Burnette
Journal:  Hematol Rep       Date:  2010-01-26

7.  Gene Expression and Methylation Pattern in HRK Apoptotic Gene in Myelodysplastic Syndrome.

Authors:  Farhad Zaker; Naser Amirizadeh; Nahid Nasiri; Seyed Mohsen Razavi; Ladan Teimoori-Toolabi; Marjan Yaghmaie; Roya Mehrasa
Journal:  Int J Mol Cell Med       Date:  2016-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.